Becton Dickinson looks to divest life sciences unit at $30 billion valuation, source says

U.S. medical device maker Becton Dickinson (BDX.N), opens new tab is considering a potential separation of its life sciences unit at a valuation of about $30 billion, a person familiar with the matter said on Monday.
The company could announce the separation of the business, which consists of biosciences and diagnostic solutions, at the time of its earnings later this week, the source said.
Becton is scheduled to report results on Thursday.